GRI Bio GRI 深 沪
等待开盘 03-26 09:30:00 美东时间
2.40
-0.030
-1.23%
华盛通- 最 高2.56
- 今 开2.47
- 成交量 3.94万股
- 最 低 2.325
- 昨 收 2.43
- 总市值 346.81万
- 52周最高 80.36
- 市盈率 静 --
- 换手率 2.73%
- 52周最低 2.10
- 委 比 -53.85%
- 总股本 144.50万
- 历史最高 64792072.80
- 量 比 1.62
- 振 幅 9.67%
- 历史最低 2.325
- 每 手 1
- 风险率 30.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
Ascendiant Capital Maintains Buy on GRI Bio, Lowers Price Target to $40
Ascendiant Capital analyst Edward Woo maintains GRI Bio (NASDAQ:GRI) with a Buy and lowers the price target from $1008 to $40.
03-11 20:44
After Trump's SOTU, Hyperscalers Told to Build Their Own Power — Grid ETFs In Focus
AI's electricity boom meets Trump's SOTU policy shift. Utilities and smart grid ETFs may be the real winners — or losers.
02-26 05:04
GRI Bio Reports Positive Phase 2a Results in Idiopathic Pulmonary Fibrosis
GRI Bio Reports Positive Phase 2a Results in Idiopathic Pulmonary Fibrosis GRI Bio Inc. announced additional positive Phase 2a clinical data for its pipeline targeting Idiopathic Pulmonary Fibrosis (IPF). The results, which include biomarker data indicating improvements in fibrosis and lung repair,
02-17 22:15
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment
GRI Bio, a biotechnology company developing NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases, participated in a Virtual Investor "What This Means" segment. Marc Hertz, CEO, discussed the company's recently reported positive Phase 2a data for GRI-0621 in Idiopathic Pulmonary Fibrosis (IPF), highlighting biomarker improvements in fibrosis drivers and lung repair. GRI Bio's therapies target iNKT cells to interrupt disease prog...
02-17 14:15
EXCLUSIVE: 'Inference Infrastructure Gap To Widen' — Bitcoin Miner Cango's AI Pivot Signals An ETF Opportunity
Crypto miner Cango is pivoting to AI infrastructure. A senior Cango executive cites growing power demand as a reason. This shift hides ETF opportunities.
02-14 22:02
GRI Bio shares are trading higher. The company reported FY25 financial results.
GRI Bio shares are trading higher. The company reported FY25 financial results.
02-04 21:58
GRI Bio FY25 Net Loss $12M
GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases today
02-04 21:56
GRI Bio raises $14.5 mln to fund operations into Q1 2027
GRI Bio raises $14.5 mln to fund operations into Q1 2027 Overview Biotechnology company raised $14.5 mln in gross proceeds to fund operations into Q1 2027 Company announced positive Phase 2a data for GRI-0621 in idiopathic pulmonary fibrosis Cash position expected to fund operations into Q1 2027 Out
02-04 21:56
BRIEF-GRI Bio May Offer Up To $250 Million In Securities - SEC Filing
BRIEF-GRI Bio May Offer Up To $250 Million In Securities - SEC Filing Jan 30 (Reuters) - GRI Bio Inc GRI.O : GRI BIO INC - MAY OFFER UP TO $250 MILLION IN SECURITIES - SEC FILING Source text: [ID:n0001824293-26-000028] Further company coverage: GRI.O (( Reuters.Briefs@thomsonreuters.com ;))
01-30 19:09
